Koji Takei

An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe

Koji Takei, Kikumi Tsuda, Fumihiro Takahashi, 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis

Koji Takei, Kikumi Tsuda, Fumihiro Takahashi, 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis

Koji Takei, Kikumi Tsuda, Fumihiro Takahashi, 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations

Koji Takei, J. Palumbo, Yoshinobu Nakamaru, 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Edaravone and its clinical development for amyotrophic lateral sclerosis

Koji Takei, J. Palumbo, S. Yuki, 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis

J. Hubble, Koji Takei, Kikumi Tsuda, 2019, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis

Koji Takei, Kikumi Tsuda, Fumihiro Takahashi, 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS‐R item scores in pivotal study MCI186‐19

E. Pioro, Koji Takei, Fumihiro Takahashi, 2021, Muscle & nerve.